振东制药
(300158)
| 流通市值：67.92亿 | | | 总市值：67.96亿 |
| 流通股本：10.05亿 | | | 总股本：10.05亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,214,507,098.61 | 1,456,942,003.34 | 754,532,591.77 | 2,971,127,572.67 |
| 营业收入 | 2,214,507,098.61 | 1,456,942,003.34 | 754,532,591.77 | 2,971,127,572.67 |
| 二、营业总成本 | 2,206,677,387.24 | 1,459,772,217.38 | 759,035,483.8 | 3,381,880,603.7 |
| 营业成本 | 1,042,476,724.91 | 711,756,735.99 | 384,133,474.79 | 1,560,125,224.31 |
| 税金及附加 | 23,775,444.1 | 16,461,680.26 | 7,659,182.76 | 30,852,129.21 |
| 销售费用 | 822,857,844.03 | 517,269,057.71 | 255,368,911.03 | 1,139,456,991.36 |
| 管理费用 | 202,244,468.16 | 136,835,641.67 | 63,126,961.31 | 301,178,511.88 |
| 研发费用 | 114,643,536.85 | 77,443,275.28 | 48,435,492.5 | 351,477,781.37 |
| 财务费用 | 679,369.19 | 5,826.47 | 311,461.42 | -1,210,034.43 |
| 其中:利息费用 | 1,097,983.34 | 738,515.79 | 558,117.52 | 3,605,558.57 |
| 其中:利息收入 | 1,576,791.74 | 1,498,277.23 | 472,329.53 | 5,671,229.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,149,900.19 | 1,328,710.16 | 845,023.58 | -139,440,121.7 |
| 加:投资收益 | 8,890,277.02 | 6,519,141.08 | 3,416,186.8 | 41,972,827.58 |
| 资产处置收益 | 707,922.86 | 4,604.73 | 250 | 11,256,735.65 |
| 资产减值损失(新) | -8,781,229.16 | -8,947,402.13 | 7,358,017.91 | -294,073,445.53 |
| 信用减值损失(新) | -1,674,305.63 | -1,789,449.56 | -797,892.23 | 3,197,892.44 |
| 其他收益 | 45,888,483.67 | 32,254,346.79 | 6,176,852.62 | 73,132,495.15 |
| 四、营业利润 | 54,010,760.32 | 26,539,737.03 | 12,495,546.65 | -714,706,647.44 |
| 加:营业外收入 | 1,206,086.03 | 1,066,477.61 | 316,788.49 | 9,290,411.66 |
| 减:营业外支出 | 9,475,536.97 | 6,695,178.32 | 6,193,253.49 | 609,605,746.66 |
| 五、利润总额 | 45,741,309.38 | 20,911,036.32 | 6,619,081.65 | -1,315,021,982.44 |
| 减:所得税费用 | 27,365,566.38 | 14,407,439.16 | 5,613,313.22 | 17,917,113.01 |
| 六、净利润 | 18,375,743 | 6,503,597.16 | 1,005,768.43 | -1,332,939,095.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 18,375,743 | 6,503,597.16 | 1,005,768.43 | -1,332,939,095.45 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 20,364,069.93 | 7,931,302.93 | 1,157,176.86 | -1,328,563,928.26 |
| 少数股东损益 | -1,988,326.93 | -1,427,705.77 | -151,408.43 | -4,375,167.19 |
| 扣除非经常损益后的净利润 | 507,544.83 | -8,176,408.91 | 289,616.69 | -686,339,926.76 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.01 | 0 | -1.3 |
| (二)稀释每股收益 | 0.02 | 0.01 | 0 | -1.3 |
| 八、其他综合收益 | -736,346.78 | -1,147,236.17 | 652.32 | -47,070,237.62 |
| 归属于母公司股东的其他综合收益 | -736,346.78 | -1,147,236.17 | 652.32 | -47,070,237.62 |
| 九、综合收益总额 | 17,639,396.22 | 5,356,360.99 | 1,006,420.75 | -1,380,009,333.07 |
| 归属于母公司股东的综合收益总额 | 19,627,723.15 | 6,784,066.76 | 1,157,829.18 | -1,375,634,165.88 |
| 归属于少数股东的综合收益总额 | -1,988,326.93 | -1,427,705.77 | -151,408.43 | -4,375,167.19 |
| 公告日期 | 2025-10-23 | 2025-08-25 | 2025-04-21 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |